However, unlike tyrosine kinase mutations occurring predominantly in non-small cell lung cancer (NSCLC), there is no known correlation between EGFR related biomarkers or specific activating mutations within the EGFR that could predict EGFR inhibitor efficacy in SCCHN [5,12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.